ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ANI Pharmaceuticals Inc. | 69 | 4.67 | 9.22M | 1.15 | 73.62 |
| Matinas BioPharma Holdings Inc. | 1 | 0.00 | 137.75M | -0.15 | 0.00 |
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Profitability
Table 2 provides us the return on equity, return on assets and net margins of both companies.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals Inc. | 13,312,157.09% | 7% | 3.1% |
| Matinas BioPharma Holdings Inc. | 20,507,667,113.29% | -157.2% | -59.6% |
Volatility & Risk
A beta of 2.16 shows that ANI Pharmaceuticals Inc. is 116.00% more volatile than Standard & Poor’s 500. Matinas BioPharma Holdings Inc.’s 73.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 1.73 beta.
Liquidity
ANI Pharmaceuticals Inc. has a Current Ratio of 0.9 and a Quick Ratio of 0.7. Competitively, Matinas BioPharma Holdings Inc.’s Current Ratio is 12.8 and has 12.8 Quick Ratio. Matinas BioPharma Holdings Inc.’s better ability to pay short and long-term obligations than ANI Pharmaceuticals Inc.
Analyst Recommendations
The next table highlights the delivered recommendations and ratings for ANI Pharmaceuticals Inc. and Matinas BioPharma Holdings Inc.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| ANI Pharmaceuticals Inc. | 0 | 0 | 1 | 3.00 |
| Matinas BioPharma Holdings Inc. | 0 | 0 | 0 | 0.00 |
The upside potential is 2.94% for ANI Pharmaceuticals Inc. with average target price of $74.5.
Institutional and Insider Ownership
Roughly 86.2% of ANI Pharmaceuticals Inc. shares are owned by institutional investors while 25.8% of Matinas BioPharma Holdings Inc. are owned by institutional investors. Insiders owned 3.3% of ANI Pharmaceuticals Inc. shares. Competitively, insiders own roughly 1.9% of Matinas BioPharma Holdings Inc.’s shares.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| ANI Pharmaceuticals Inc. | 1.72% | 2.27% | 20.43% | 55.98% | 25.49% | 87.89% |
| Matinas BioPharma Holdings Inc. | 3.84% | -5.27% | -18.89% | -17.23% | 114.58% | 36.32% |
For the past year ANI Pharmaceuticals Inc. has stronger performance than Matinas BioPharma Holdings Inc.
Summary
On 8 of the 12 factors ANI Pharmaceuticals Inc. beats Matinas BioPharma Holdings Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
